In March 2017, the following letter was sent to relevant healthcare professionals to inform them of updated safety information:
- Nulojix (belatacept) 250 mg:
—restricted to existing patients
We are also aware of the following letter, which was sent to relevant healthcare professionals in October 2016:
- Mucodyne Paediatric Syrup 250 mg/5 mL (carbocisteine oral liquid):
—check dose volume to ensure appropriate dose is given
Article citation: Drug Safety Update volume 10, issue 9, April 2017: 4.